Applied DNA to Hold Investment Community Meetings During the JP Morgan 38th Annual Healthcare Conference and Present at the Biotech Showcase 2020
STONY BROOK, N.Y.--(BUSINESS WIRE)--Jan 10, 2020--
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, today announced that CEO Dr. James A. Hayward and leadership of the Company’s majority-owned subsidiary, LineaRx, Inc., will be meeting with members of the global investment community from January 13 to 15, 2020 in San Francisco concurrent with the JP Morgan 38 th Annual Healthcare Conference, the world’s largest healthcare investment symposium.
In addition, Dr. Hayward will present an overview of the Company, including its supply chain platform, its diagnostic platform for the blood-based capture of metastatic cells, and review the linear DNA platforms in nucleic acid delivery, gene expression, non-integrated DNA replication, and its robust pipeline of more than 15 contract research opportunities with top cancer, gene therapy, vaccine and RNA partners at the Biotech Showcase 2020 at 3:00 pm PT on Tuesday, January 14, 2020. Dr. Hayward’s presentation will be webcast live at: https://event.webcasts.com/starthere.jsp?ei=1279407&tp_key=6924765b8a.
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture. LineaRx is also developing a liquid biopsy form for isolating metastatic cells from blood. Go to www.adnas.com for more information on LineaRx and to learn more about how Applied DNA makes life real and safe. LineaRx is a majority-owned Applied DNA Sciences, Inc. (Nasdaq: APDN) company.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Common stock listed on NASDAQ under the symbol APDN.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partners product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200110005066/en/
CONTACT: Investor contact: Sanjay M. Hurry, 212-838-3777, LHA Investor Relations,firstname.lastname@example.org
KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SUPPLY CHAIN MANAGEMENT ONCOLOGY RETAIL HEALTH GENETICS BIOTECHNOLOGY
SOURCE: Applied DNA Sciences, Inc.
Copyright Business Wire 2020.
PUB: 01/10/2020 09:00 AM/DISC: 01/10/2020 09:01 AM